REGINfo: NOVARTIS - Chimie de spécialité - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$NOVARTIS: Click to view the issuer\'s details$

Last update : 28/01/2011 >View issuer details

2019.07.01 | 17:30 | Permanent Information Releases / General Company News

puce Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio - HTML (w)

2019.06.14 | 08:30 | Permanent Information Releases / Sales and Revenues

puce Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna® use and promising combination data with investigational compound asciminib (ABL001) - HTML (w)

2019.06.12 | 07:20 | Permanent Information Releases / General Company News

puce Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show - HTML (w)

2019.06.12 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis - HTML (w)

2019.06.07 | 07:00 | Permanent Information Releases / General Company News

puce Novartis announces new leader of Pharmaceuticals Business Unit - HTML (w)

2019.06.07 | 07:00 | Permanent Information Releases / General Company News

puce Novartis stellt neue Leiterin der Pharmaceuticals Business Unit vor - HTML (w)

2019.06.06 | 07:15 | Permanent Information Releases / General Company News

puce Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible - HTML (w)

2019.06.04 | 19:00 | Permanent Information Releases / General Company News

puce Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist® - HTML (w)

2019.06.03 | 07:15 | Permanent Information Releases / General Company News

puce Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials - HTML (w)

2019.06.03 | 07:00 | Permanent Information Releases / General Company News

puce Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies - HTML (w)

2019.06.01 | 13:30 | Permanent Information Releases / General Company News

puce Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial - HTML (w)

2019.05.30 | 07:15 | Permanent Information Releases / General Company News

puce Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma - HTML (w)

2019.05.24 | 22:12 | Permanent Information Releases / General Company News

puce FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer - HTML (w)

2019.05.24 | 18:42 | Permanent Information Releases / General Company News

puce AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families - HTML (w)

2019.05.24 | 18:31 | Permanent Information Releases / General Company News

puce AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA) - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1225